Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis

Acta Biochim Pol. 2019 Dec 17;66(4):463-467. doi: 10.18388/abp.2019_2863.

Abstract

The presented investigation explores the efficiency of novel transdermal drug delivery system of combination of two drugs i.e risedronate and alendronate in the treatment of osteoporosis. The nanoparticulate transdermal patch was prepared using PLGA as principle polymer which has been found to be suitable for drug delivery. The novel formulation system was found to be more efficient in lowering and maintaining the plasma calcium at a normal level when compared to a pure drug in a study carried out on an excised rat skin.

MeSH terms

  • Alendronate / administration & dosage*
  • Animals
  • Bone Density Conservation Agents / administration & dosage
  • Calcium / blood
  • Drug Delivery Systems / methods*
  • Drug Therapy, Combination / methods
  • Female
  • Osteoporosis / drug therapy*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rats
  • Risedronic Acid / administration & dosage*
  • Transdermal Patch

Substances

  • Bone Density Conservation Agents
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Risedronic Acid
  • Calcium
  • Alendronate